Mystery Shopper Arana Stops Trading On ASX Until “Take Over” Announced
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Aussie biotech Arana announced Feb. 26 that it has engaged in take-over discussions and halted trading on the Australian Stock Exchange in anticipation of the take over
You may also be interested in...
Cephalon Launches Takeover Bid For Australian Biotech Arana
Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.
Cephalon Launches Takeover Bid For Australian Biotech Arana
PERTH, Australia - Sydney-based biotech Arana Therapeutics announced Feb. 27 that Cephalon intends to make a cash takeover offer for all of Arana's shares at a price of $1.40 per share
Cephalon Launches Takeover Bid For Australian Biotech Arana
Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.